[go: up one dir, main page]

AR088109A1 - Metodo para preparar analogos nucleotidicos antivirales - Google Patents

Metodo para preparar analogos nucleotidicos antivirales

Info

Publication number
AR088109A1
AR088109A1 ARP120103681A AR088109A1 AR 088109 A1 AR088109 A1 AR 088109A1 AR P120103681 A ARP120103681 A AR P120103681A AR 088109 A1 AR088109 A1 AR 088109A1
Authority
AR
Argentina
Prior art keywords
formula
compound
diastereomerically pure
phenoxyphosphinyl
isopropoxycarbonyl
Prior art date
Application number
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR088109A1 publication Critical patent/AR088109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Métodos para aislar 9-{(R)-2-[((S)-{[(S)-1-(isopropoxicarbonil)etil]amino}-fenoxifosfinil)metoxi]propil}adenina compuesto de fórmula (1) y métodos para preparar compuestos relacionados, tiene propiedades antivirales. Reivindicación 1: Un método que comprende someter una solución que comprende: a) un solvente adecuado; b) una base adecuada; y c) 9-{(R)-2-[((R,S)-[(S)-1-(isopropoxicarbonil)etil]amino}fenoxifosfinil)metoxi]propil}adenina, a condiciones que proporcionan la cristalización selectiva de 9-{(R)-2-[((S)-{[(S)-1-(isopropoxicarbonil)etil]amino}fenxifosfinil)metoxi]propil}adenina. Reivindicación 9: Un método para preparar el compuesto de fórmula (2), donde X es halo, que es por lo menos aproximadamente 90% diastereoméricamente puro, que comprende tratar el compuesto de fórmula (3) con un agente halogenante adecuado bajo condiciones que proporcionan el compuesto de fórmula (2) que es por lo menos aproximadamente 90% diastereoméricamente puro. Reivindicación 14: Un método para preparar el compuesto de fórmula (4) que es el compuesto de fórmula (1) por lo menos aproximadamente 90% diastereoméricamente puro que comprende tratar el compuesto de fórmula (2) donde X es halo, que es por lo menos aproximadamente 90% diastereoméricamente puro, con la amina de fórmula (5) bajo condiciones que proporcionan el compuesto de fórmula (4) que es el compuesto de fórmula (1) por lo menos aproximadamente 90% diastereoméricamente puro.
ARP120103681 2014-04-11 2012-10-03 Metodo para preparar analogos nucleotidicos antivirales AR088109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161544950P 2014-04-11 2014-04-11

Publications (1)

Publication Number Publication Date
AR088109A1 true AR088109A1 (es) 2014-05-07

Family

ID=47297386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103681 AR088109A1 (es) 2014-04-11 2012-10-03 Metodo para preparar analogos nucleotidicos antivirales

Country Status (25)

Country Link
US (4) US8664386B2 (es)
EP (2) EP2764002B1 (es)
JP (2) JP6190372B2 (es)
KR (3) KR102033802B1 (es)
CN (4) CN107266498B (es)
AR (1) AR088109A1 (es)
AU (3) AU2012319172B2 (es)
BR (2) BR112014011340A2 (es)
CA (2) CA2850466C (es)
CL (1) CL2014000827A1 (es)
CO (1) CO6940431A2 (es)
CR (1) CR20140204A (es)
EA (1) EA027086B1 (es)
EC (1) ECSP14000074A (es)
ES (2) ES2746859T3 (es)
HK (1) HK1255222B (es)
IL (1) IL231879B (es)
MX (1) MX353064B (es)
PE (1) PE20141160A1 (es)
PL (1) PL3333173T3 (es)
PT (2) PT2764002T (es)
SI (1) SI3333173T1 (es)
TW (4) TWI709567B (es)
UY (1) UY34361A (es)
WO (1) WO2013052094A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN01012A (es) 2011-08-16 2015-05-15 Gilead Sciences Inc
ES2746859T3 (es) 2014-04-11 2020-03-09 Gilead Sciences Inc Métodos para la preparación de análogos de nucleótidos antivirales
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9676803B2 (en) 2013-06-07 2017-06-13 Cipla Limited Efficient process for separation of diastereomers of 9-[(R)-2-[[(R,S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine
CN104628773B (zh) * 2013-11-06 2018-10-23 杭州和泽医药科技有限公司 (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法
WO2015079455A2 (en) * 2013-11-27 2015-06-04 Laurus Labs Private Limited A recycling process for preparing tenofovir alafenamide diastereomers
IN2014MU00118A (es) * 2014-01-14 2015-08-28 Mylan Lab Ltd
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
WO2015161785A1 (zh) * 2014-04-21 2015-10-29 四川海思科制药有限公司 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
CN105518012B (zh) * 2014-06-25 2018-03-02 四川海思科制药有限公司 一种取代的氨基酸硫酯类化合物、其组合物及应用
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
CN108148094A (zh) * 2014-11-12 2018-06-12 四川海思科制药有限公司 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途
CN104817593B (zh) * 2015-04-27 2016-11-16 广州同隽医药科技有限公司 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺
PT3331891T (pt) 2015-08-05 2022-02-28 Eisai R&D Man Co Ltd Um método para preparar um oligómero de fosforodiamidato substancialmente diastereomericamente puro, um oligómero de fosforodiamidato feito por tal método e uma composição farmacêutica que compreende tal oligómero de fosforodiamidato
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
CN105330700A (zh) * 2015-12-17 2016-02-17 中国药科大学 富马酸替诺福韦艾拉酚胺杂质的制备方法
WO2017118928A1 (en) 2016-01-06 2017-07-13 Lupin Limited Process for the separation of diastereomers of tenofovir alafenamide
CZ2016156A3 (cs) * 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107286190A (zh) * 2016-04-13 2017-10-24 刘沛 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN106946935B (zh) * 2017-04-28 2020-01-07 福建广生堂药业股份有限公司 一种非对映异构体核苷衍生物的制备方法
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
WO2019070827A1 (en) * 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN110092803A (zh) * 2018-01-31 2019-08-06 北京睿创康泰医药研究院有限公司 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用
CN108409788B (zh) * 2018-03-12 2020-05-08 科兴生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺的制备方法
CN110305163A (zh) * 2018-03-27 2019-10-08 北京济美堂医药研究有限公司 替诺福韦艾拉酚胺半富马酸盐的制备方法
CN108467410B (zh) * 2018-04-09 2021-04-09 重庆三圣实业股份有限公司 一种taf中间体的制备方法及产品和应用
CN108484672A (zh) * 2018-05-23 2018-09-04 中国药科大学制药有限公司 磷丙替诺福韦的手性拆分方法
CN108822149B (zh) * 2018-06-01 2020-08-11 成都苑东生物制药股份有限公司 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法
CN110283208B (zh) * 2018-06-22 2022-07-08 南京济群医药科技股份有限公司 一种替诺福韦艾拉酚胺的手性拆分方法
CN109081853A (zh) * 2018-09-03 2018-12-25 南京正大天晴制药有限公司 一种磷丙替诺福韦有关物质的制备方法
CN111484527A (zh) * 2019-01-25 2020-08-04 上海清松制药有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN119462659A (zh) 2019-03-22 2025-02-18 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其药学用途
CN111943981A (zh) * 2019-05-14 2020-11-17 博瑞生物医药泰兴市有限公司 一种磷丙替诺福韦的制备方法
CN114409706B (zh) * 2019-07-01 2023-11-28 上海医药工业研究院 一种苯基氢膦酸酯及其中间体的制备方法
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN112390824B (zh) * 2019-08-19 2022-07-05 鲁南制药集团股份有限公司 一种替诺福韦艾拉酚胺中间体的制备方法
CN110981911A (zh) * 2019-10-08 2020-04-10 浙江车头制药股份有限公司 一种替诺福韦艾拉酚胺的制备方法
CN111171076A (zh) * 2019-12-26 2020-05-19 合肥启旸生物科技有限公司 一种替诺福韦二聚体的制备方法
EP4121437A1 (en) 2020-03-20 2023-01-25 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
KR20230107288A (ko) 2020-11-11 2023-07-14 길리애드 사이언시즈, 인코포레이티드 gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
FI4445900T3 (fi) 2021-12-03 2025-08-05 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP4577242A1 (en) 2022-08-26 2025-07-02 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025080863A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US8318701B2 (en) * 2004-07-27 2012-11-27 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
WO2007126812A2 (en) 2006-03-29 2007-11-08 Gilead Sciences, Inc. Process for preparation of hiv protease inhibitors
TWI399377B (zh) * 2006-07-07 2013-06-21 Gilead Sciences Inc 類鐸受體７之調節劑
WO2008011116A2 (en) * 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
SG174016A1 (en) * 2006-07-24 2011-09-29 Korea Res Inst Chem Tech Hiv reverse transcriptase inhibitors
US8354421B2 (en) * 2007-06-29 2013-01-15 Korea Research Insitute Of Chemical Technology HIV reverse transcriptase inhibitors
IN2014DN01012A (es) 2011-08-16 2015-05-15 Gilead Sciences Inc
ES2746859T3 (es) 2014-04-11 2020-03-09 Gilead Sciences Inc Métodos para la preparación de análogos de nucleótidos antivirales

Also Published As

Publication number Publication date
EP3333173A1 (en) 2018-06-13
AU2014215976B2 (en) 2016-06-30
WO2013052094A2 (en) 2013-04-11
KR102033802B1 (ko) 2019-10-17
TWI689513B (zh) 2020-04-01
CN103842366A (zh) 2014-06-04
CL2014000827A1 (es) 2014-09-05
CA3042169C (en) 2021-09-07
MX2014003952A (es) 2014-08-01
TWI613211B (zh) 2018-02-01
IL231879B (en) 2019-11-28
HK1245798A1 (zh) 2018-08-31
TW202003531A (zh) 2020-01-16
US9029534B2 (en) 2015-05-12
KR20200090975A (ko) 2020-07-29
EP2764002B1 (en) 2018-02-28
PT2764002T (pt) 2018-05-16
EP2764002A2 (en) 2014-08-13
TW201716418A (zh) 2017-05-16
CN117343101A (zh) 2024-01-05
EA027086B1 (ru) 2017-06-30
ES2661705T3 (es) 2018-04-03
TWI557133B (zh) 2016-11-11
US20150291638A1 (en) 2015-10-15
CN107266498B (zh) 2023-10-03
NZ624513A (en) 2016-06-24
KR20140090170A (ko) 2014-07-16
CN107266498A (zh) 2017-10-20
KR20190086576A (ko) 2019-07-22
JP6190372B2 (ja) 2017-08-30
AU2016228317B2 (en) 2018-07-19
ECSP14000074A (es) 2016-01-29
EA201490753A1 (ru) 2014-09-30
TW201811808A (zh) 2018-04-01
PL3333173T3 (pl) 2019-12-31
AU2012319172B2 (en) 2014-06-12
TW201331218A (zh) 2013-08-01
HK1200834A1 (en) 2015-08-14
AU2012319172A1 (en) 2013-05-16
BR112014011340A2 (pt) 2017-06-13
PT3333173T (pt) 2019-09-10
ES2746859T3 (es) 2020-03-09
CA2850466A1 (en) 2013-04-11
UY34361A (es) 2013-05-31
BR102014008928B1 (pt) 2022-05-17
TWI709567B (zh) 2020-11-11
KR102139440B1 (ko) 2020-07-29
US20140128602A1 (en) 2014-05-08
CN103842366B (zh) 2017-06-16
BR102014008928A2 (pt) 2015-12-08
HK1255222B (en) 2020-07-17
PE20141160A1 (es) 2014-09-22
MX353064B (es) 2017-12-19
CA2850466C (en) 2020-07-28
JP2017160228A (ja) 2017-09-14
CO6940431A2 (es) 2014-05-09
US8664386B2 (en) 2014-03-04
US20130090473A1 (en) 2013-04-11
EP3333173B1 (en) 2019-06-26
AU2016228317A1 (en) 2016-10-06
CN113264959A (zh) 2021-08-17
US9346841B2 (en) 2016-05-24
US9676804B2 (en) 2017-06-13
SI3333173T1 (sl) 2019-08-30
WO2013052094A3 (en) 2013-06-20
US20160311840A1 (en) 2016-10-27
JP2014530809A (ja) 2014-11-20
CA3042169A1 (en) 2013-04-11
AU2014215976A1 (en) 2014-09-11
CR20140204A (es) 2014-06-03

Similar Documents

Publication Publication Date Title
AR088109A1 (es) Metodo para preparar analogos nucleotidicos antivirales
IN2014MU00118A (es)
CR20170571A (es) Nuevos derivados aminoácido, un proceso para su preparación y composiciones farmaceúticas que los contienen.
AR105050A1 (es) Procesos para preparar compuestos antivirales
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
CR20180363A (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
MX2017006942A (es) Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
MX2018001966A (es) Deshidrohalogenacion de hidroclorofluorocarburos.
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
BR112019025028A2 (pt) Método para preparar um composto.
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
BR112017028088A2 (pt) ?composição de barra de limpeza, utilização da composição, processo para preparar a composição e método de limpeza de uma superfície?
BR112017020380A2 (pt) processo para separar hidrocarbonetos de uma solução compreendendo um polímero
BR112012019866A2 (pt) composto, composição farmacêutica, método de tratamento das infecções virais, e, processo para preparar um composto
MX2017001459A (es) Sintesis de fosforamidatos.
CL2015003037A1 (es) Derivados de triazina
AR107419A1 (es) Proceso para la preparación de ácidos 4-alcoxi-3-acetoxipicolínicos
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
CO7160053A2 (es) Proceso para el tratamiento de hidrocarburos licuados usando compuestos de 3-(amino)propan-1,2-diol
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
AR099070A1 (es) Ácido (s)- 3-metil-abscísico y ésteres del mismo

Legal Events

Date Code Title Description
FC Refusal